Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood.

Fiche publication

Date publication

juin 2021

Journal

BMC immunology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ADOTEVI Olivier , Dr MARTIN Etienne , Dr MIRJOLET Céline , Dr VULQUIN Noémie , Dr BOUSTANI Jihane

Tous les auteurs :
Boustani J, Joseph ELM, Martin E, Benhmida S, Lecoester B, Tochet F, Mirjolet C, Chevalier C, Thibouw D, Vulquin N, Servagi S, Sun X, Adotévi O

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34144673

Résumé

The synergistic effect of chemoradiation (CRT) has been previously demonstrated in several cancer types. Here, we investigated the systemic immune effects of CRT in patients with lung or head and neck cancer.